Key Points
- CEO Claire Mazumdar sold 60,000 BCAX shares in multiple March transactions, raising roughly $1.14 million at average prices around $18.7–$19.2 per share.
- After the sales she still owns 339,392 shares (a 1.88% reduction, valued at about $6.39 million); BCAX is trading near $18.41, is down about 2%, and carries a consensus analyst target of $30.25 ("Moderate Buy").
Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) CEO Claire Mazumdar sold 1,596 shares of the company's stock in a transaction dated Friday, March 20th. The shares were sold at an average price of $18.95, for a total transaction of $30,244.20. Following the completion of the sale, the chief executive officer directly owned 339,392 shares of the company's stock, valued at $6,431,478.40. The trade was a 0.47% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Claire Mazumdar also recently made the following trade(s):
- On Wednesday, March 18th, Claire Mazumdar sold 6,499 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.84, for a total transaction of $122,441.16.
- On Thursday, March 19th, Claire Mazumdar sold 6,905 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.78, for a total transaction of $129,675.90.
- On Monday, March 9th, Claire Mazumdar sold 36,766 shares of Bicara Therapeutics stock. The shares were sold at an average price of $19.17, for a total value of $704,804.22.
- On Friday, March 6th, Claire Mazumdar sold 3,817 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.75, for a total value of $71,568.75.
- On Wednesday, March 4th, Claire Mazumdar sold 2,631 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.73, for a total value of $49,278.63.
- On Thursday, March 5th, Claire Mazumdar sold 1,786 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.74, for a total value of $33,469.64.
Bicara Therapeutics Stock Down 2.0%
Shares of Bicara Therapeutics stock opened at $18.41 on Friday. Bicara Therapeutics Inc. has a 12-month low of $7.80 and a 12-month high of $20.25. The firm has a market capitalization of $1.01 billion, a PE ratio of -8.22 and a beta of -0.78. The stock's fifty day moving average is $16.98 and its 200-day moving average is $16.27.
Hedge Funds Weigh In On Bicara Therapeutics
Large investors have recently bought and sold shares of the stock. Legal & General Group Plc raised its stake in Bicara Therapeutics by 64.1% during the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company's stock valued at $29,000 after purchasing an additional 1,233 shares during the last quarter. Ameritas Investment Partners Inc. grew its position in Bicara Therapeutics by 73.0% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,493 shares of the company's stock worth $32,000 after purchasing an additional 1,474 shares during the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of Bicara Therapeutics by 419.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company's stock worth $44,000 after purchasing an additional 3,866 shares during the period. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Bicara Therapeutics during the fourth quarter valued at about $45,000. Finally, Larson Financial Group LLC raised its position in shares of Bicara Therapeutics by 1,015.5% during the third quarter. Larson Financial Group LLC now owns 3,949 shares of the company's stock valued at $62,000 after buying an additional 3,595 shares during the last quarter.
Wall Street Analyst Weigh In
A number of research analysts have recently weighed in on BCAX shares. Mizuho upgraded Bicara Therapeutics to a "hold" rating in a report on Thursday, December 18th. Citigroup initiated coverage on Bicara Therapeutics in a research note on Thursday, January 29th. They issued an "outperform" rating on the stock. HC Wainwright reiterated a "buy" rating on shares of Bicara Therapeutics in a research note on Wednesday, January 14th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Bicara Therapeutics in a report on Friday, January 9th. Finally, Wedbush restated an "outperform" rating and set a $30.00 price target on shares of Bicara Therapeutics in a report on Tuesday, January 13th. Six analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $30.25.
Check Out Our Latest Report on Bicara Therapeutics
Bicara Therapeutics Company Profile
(
Get Free Report)
Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company's research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.
The company's lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
